SEARCH

SEARCH BY CITATION

References

  • 1
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004;172:9104.
  • 2
    Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics–theory. Urology 1981;17:4053.
  • 3
    Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010;71:496504.
  • 4
    Nesslinger NJ, Sahota RA, Stone B et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493502.
  • 5
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:24552.
  • 6
    Ridolfi R, Petrini M, Fiammenghi L et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006;16:36.
  • 7
    Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:40917.
  • 8
    Lee HJ, Hong CY, Kim MH et al. In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med 2012;44:607.
  • 9
    Yang DH, Kim MH, Hong CY et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol 2010;89:795801.
  • 10
    Jonuleit H, Kuhn U, Muller G et al. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:313542.
  • 11
    Ridolfi L, Petrini M, Fiammenghi L et al. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 2011;21:5249.
  • 12
    Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:56370.
  • 13
    Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13:90518.
  • 14
    Pedersen AE, Thorn M, Gad M et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol 2006;61:156.
  • 15
    Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:59347.
  • 16
    Nguyen-Pham TN, Lee YK, Lee HJ et al. Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol 2012;47:1727.
  • 17
    Matera L. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev 2010;36:13141.
  • 18
    Lee JJ, Choi BH, Kang HK et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma 2007;48:202231.
  • 19
    Palucka AK, Ueno H, Connolly J et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006;29:54557.
  • 20
    Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797803.
  • 21
    Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000;43:88100.
  • 22
    Murphy GP, Tjoa BA, Simmons SJ et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:549.
  • 23
    Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894903.
  • 24
    Pavlenko M, Roos AK, Lundqvist A et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91:68894.
  • 25
    Kobayashi K, Noguchi M, Itoh K, Harada M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 2003;94:6227.
  • 26
    Correale P, Walmsley K, Nieroda C et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293300.
  • 27
    Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099105.
  • 28
    Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:41122.
  • 29
    Schreibelt G, Tel J, Sliepen KH et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010;59:157382.
  • 30
    Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007;56:817.
  • 31
    Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009;69:57184.
  • 32
    Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist 2006;11:45162.
  • 33
    Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008;68:59728.
  • 34
    Watchmaker PB, Berk E, Muthuswamy R et al. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 2010;184:5917.
  • 35
    Wieckowski E, Chatta GS, Mailliard RM et al. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate 2011;71:12533.
  • 36
    Joniau S, Abrahamsson PA, Bellmunt J et al. Current Vaccination Strategies for Prostate Cancer. Eur Urol 2012;61:290306.
  • 37
    Delirezh N, Moazzeni SM, Shokri F, Shokrqozar MA, Atri M, Kokhaei P. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol 2009;257:2331.
  • 38
    Park MH, Yang DH, Kim MH et al. Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer. Cancer Res Treat 2011;43:5666.
  • 39
    Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006;55:81929.